Oppenheimer Reiterates Outperform Rating on MannKind (MNKD) as 'Key Tyvaso DPI Approval Received'
Tweet Send to a Friend
Oppenheimer analyst Steven Lichtman reiterated an Outperform rating and $5.50 price target on MannKind (NASDAQ: MNKD) following FDA approval for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
